Eli Lilly and Company (NYSE:LLY) has become one of the pharmaceutical industry’s most important growth stories, but its valuation presents a harder question than whether demand for obesity treatments will continue to rise. Investors must decide how much of that growth remains ahead, and how much is already reflected in the share price.
Lilly’s shares closed at $1,188.72 on October 7, 2026, according to Yahoo Finance, approximately 41% above their October 7, 2025 closing price of $843.63, based on Yahoo Finance’s historical data. That substantial gain reflects a business whose earnings potential has expanded rapidly, but it also raises the bar for future results. But before we dive into Lilly’s investment case, there are nine healthcare stocks other than LLY in our ranking of the best healthcare stocks to buy according to hedge funds. Check out the complete list here.
Growth Is Supporting the Premium
One of the most watched competitions in the GLP-1 market is between Lilly and Novo Nordisk. Read more about how their investment cases compare to each other in our insightful article on Can Eli Lilly Catch Novo Nordisk in the Oral GLP-1 Race?.
Eli Lilly and Company (NYSE:LLY) trades at a forward P/E of 32.09, at a 71.70% premium to the sector. Lilly’s second-quarter results explain why investors have been willing to pay more for its shares. Revenue increased 48% year over year to $23.0 billion, while non-GAAP earnings per share rose 33% to $8.38. The company also raised its 2026 revenue guidance to $85 billion-$87 billion. Its adjusted EPS guidance, however, stands at $35.50-$36.50, following acquisition-related research and development charges that offset an improvement in underlying earnings expectations.
Lilly recorded $3.03 per share in acquired in-process research and development charges during the quarter. These expenses weighed on reported and adjusted earnings, illustrating how acquisitions can strengthen a company’s future product portfolio while creating near-term accounting costs.
More importantly, the growth is coming from products with substantial commercial momentum. Mounjaro, Lilly’s tirzepatide treatment for type 2 diabetes, and Zepbound, its obesity treatment, are driving demand across the expanding market for incretin-based medicines. Revenue from Lilly’s key products in immunology, oncology, and neuroscience also grew 121% year over year in the second quarter, offering evidence that its growth opportunities extend beyond its leading diabetes and obesity franchise.
This is the strongest argument for Lilly’s premium, as investors are not just valuing it as a mature pharmaceutical business with modest growth. They are paying for a company expanding its earnings base while developing additional products that could sustain growth over a longer period. We meticulously crafted a list of the 7 Best Pharma Stocks to Invest In Now. Access the complete list here.
The Next Phase of Growth Matters More Than the Last
Lilly’s pipeline gives that argument further substance. Foundayo, its oral GLP-1 treatment, offers a way to reach patients who prefer a pill to an injection. The company reported positive cardiovascular-safety results from its ACHIEVE-4 trial on September 30, 2026. Retatrutide, an investigational triple-hormone receptor agonist, is another potential growth driver, with Lilly reporting positive Phase 3 results across multiple trials and plans to submit it to the FDA in the first quarter of 2027.
These developments could extend Lilly’s commercial opportunity through different treatment formats and potentially new patient populations. Yet pipeline success should not be treated as revenue already earned, and it is essential to keep in mind regulatory decisions, commercial uptake, manufacturing capacity, and competition, which would help determine how much of that opportunity translates into future profits. For an expanded insight into the company’s bull and bear case, read Eli Lilly vs. Novo Nordisk: Has GLP-1 Manufacturing Become the New Competitive Moat?.
The Risk Is That Growth Does Not Translate Into Enough Earnings
Lilly’s second-quarter results also contained a warning worth watching. Revenue benefited from a 60% increase in volume, but a 13% decline in realized prices partially offset that growth. The figures do not, by themselves, establish a long-term pricing problem, but they do show why investors need to look beyond sales growth and examine how much revenue the company retains from each unit sold.
Pricing, access to treatment, competition and manufacturing costs could all influence how quickly sales growth flows through to profits. Lilly also faces the challenge of sustaining its lead as rivals develop competing medicines and as oral treatments potentially broaden the range of options available to patients. Read more extensively about Lilly’s bull and bear case here.
Lilly Must Keep Growing Into Its Valuation
Lilly’s business performance gives investors a credible reason to accept a premium over slower-growing pharmaceutical companies. Strong revenue growth, expanding therapeutic opportunities, and a promising pipeline suggest that the company’s future is not limited to its current blockbuster medicines.
But a strong business is not automatically a strong investment at every price. The critical issue is whether Eli Lilly and Company (NYSE:LLY) can convert its expanding market opportunity into sustained earnings growth at a pace that justifies what investors are paying today.
For now, Lilly’s valuation reflects confidence in continued execution. Its next phase of growth must demonstrate that this confidence is warranted, not simply through rising sales, but through durable profitability as pricing, competition, and access shape the economics of its medicines.
READ NEXT: Can Eli Lilly Catch Novo Nordisk in the Oral GLP-1 Race? AND Abbott vs. Intuitive Surgical: Is Consistent Growth Better Than Premium Growth?
This article is originally published at Insider Monkey.
Hedge Fund Resource Center